Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by jjwilsonon Sep 14, 2018 4:52pm
128 Views
Post# 28623837

RE:Clinical Trials

RE:Clinical TrialsWe need a deal - true!

We just hired the guy who will get us a deal (on PD) IMO.  Now, even in the backwoods of Canada, I expect that getting a deal would have a positive effect on the share price but I ask you - would the positive effect be greater if PMN was listed on the NASDAQ?

In your post to me (a few posts back) you mentioned that PMN has been putting out RAH RAH scientific updates for so long that the market has become bored with them and will no longer respond and that they need to put out something different.  Announcing that we poached a VP from Pfizer should count as something different and I believe that if we were trading on the NASDAQ that this would have been seen as a significant step forward instead of how it was perceived on the TSX - just another day. 

Bullboard Posts